Home > Insider Trading > Filing (0000899243-19-019173)

Filing Details

Accession Number:: 0000899243-19-019173
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-07-03 16:30:24
Reporting Period:: 2019-07-01

Accepted Time:: 2019-07-03 16:30:24
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1743881	Bridgebio Pharma Inc.	BBIO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1081714	R Henry Kravis	9 West 57Th Street, Suite 4200 New York NY 10019	No	No	Yes	No
1081715	R George Roberts	2800 Sand Hill Road, Suite 200 Menlo Park CA 94025	No	No	Yes	No
1404912	Kkr & Co. Inc.	9 West 57Th Street, Suite 4200 New York NY 10019	No	No	Yes	No
1472692	Kkr Management Holdings Corp	9 West 57Th Street, Suite 4200 New York NY 10019	No	No	Yes	No
1472693	L.p. Holdings Management Kkr	9 West 57Th Street, Suite 4200 New York NY 10019	No	No	Yes	No
1472694	Kkr Management Llc	9 West 57Th Street, Suite 4200 New York NY 10019	No	No	Yes	No
1743754	Kkr Group Holdings Corp.	9 West 57Th Street, Suite 4200 New York NY 10019	No	No	Yes	No
1780408	L.p. Disorder Genetic Kkr	9 West 57Th Street, Suite 4200 New York NY 10019	No	No	Yes	No
1780428	Kkr Genetic Disorder Gp Llc	9 West 57Th Street, Suite 4200 New York NY 10019	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-07-01	34,253,561	$0.00	34,253,561	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2019-07-01	2,647,100	$17.00	36,900,661	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Units	Disposition	2019-07-01	81,022,727	$0.00	15,859,312	$0.00
Common Stock	Series C Preferred Units	Disposition	2019-07-01	36,246,893	$0.00	8,215,295	$0.00
Common Stock	Series D Preferred Units	Disposition	2019-07-01	50,446,451	$0.00	10,178,954	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.
The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.
Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.